Cargando…

Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review

Liver disease is a leading cause of mortality worldwide, resulting in 1.3 million deaths annually. The vast majority of liver disease is caused by metabolic disease (i.e., NASH) and alcohol-induced hepatitis, and to a lesser extent by acute and chronic viral infection. Furthermore, multiple insults...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogliotti, Yanina, Vander Roest, Mark, Mattis, Aras N., Gish, Robert G., Peltz, Gary, Anwyl, Robin, Kivlighn, Salah, Schuur, Eric R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265349/
https://www.ncbi.nlm.nih.gov/pubmed/35805080
http://dx.doi.org/10.3390/cells11131998
_version_ 1784743191549837312
author Bogliotti, Yanina
Vander Roest, Mark
Mattis, Aras N.
Gish, Robert G.
Peltz, Gary
Anwyl, Robin
Kivlighn, Salah
Schuur, Eric R.
author_facet Bogliotti, Yanina
Vander Roest, Mark
Mattis, Aras N.
Gish, Robert G.
Peltz, Gary
Anwyl, Robin
Kivlighn, Salah
Schuur, Eric R.
author_sort Bogliotti, Yanina
collection PubMed
description Liver disease is a leading cause of mortality worldwide, resulting in 1.3 million deaths annually. The vast majority of liver disease is caused by metabolic disease (i.e., NASH) and alcohol-induced hepatitis, and to a lesser extent by acute and chronic viral infection. Furthermore, multiple insults to the liver is becoming common due to the prevalence of metabolic and alcohol-related liver diseases. Despite this rising prevalence of liver disease, there are few treatment options: there are treatments for viral hepatitis C and there is vaccination for hepatitis B. Aside from the management of metabolic syndrome, no direct liver therapy has shown clinical efficacy for metabolic liver disease, there is very little for acute alcohol-induced liver disease, and liver transplantation remains the only effective treatment for late-stage liver disease. Traditional pharmacologic interventions have failed to appreciably impact the pathophysiology of alcohol-related liver disease or end-stage liver disease. The difficulties associated with developing liver-specific therapies result from three factors that are common to late-stage liver disease arising from any cause: hepatocyte injury, inflammation, and aberrant tissue healing. Hepatocyte injury results in tissue damage with inflammation, which sensitizes the liver to additional hepatocyte injury and stimulates hepatic stellate cells and aberrant tissue healing responses. In the setting of chronic liver insults, there is progressive scarring, the loss of hepatocyte function, and hemodynamic dysregulation. Regenerative strategies using hepatocyte-like cells that are manufactured from mesenchymal stromal cells may be able to correct this pathophysiology through multiple mechanisms of action. Preclinical studies support their effectiveness and recent clinical studies suggest that cell replacement therapy can be safe and effective in patients with liver disease for whom there is no other option.
format Online
Article
Text
id pubmed-9265349
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92653492022-07-09 Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review Bogliotti, Yanina Vander Roest, Mark Mattis, Aras N. Gish, Robert G. Peltz, Gary Anwyl, Robin Kivlighn, Salah Schuur, Eric R. Cells Review Liver disease is a leading cause of mortality worldwide, resulting in 1.3 million deaths annually. The vast majority of liver disease is caused by metabolic disease (i.e., NASH) and alcohol-induced hepatitis, and to a lesser extent by acute and chronic viral infection. Furthermore, multiple insults to the liver is becoming common due to the prevalence of metabolic and alcohol-related liver diseases. Despite this rising prevalence of liver disease, there are few treatment options: there are treatments for viral hepatitis C and there is vaccination for hepatitis B. Aside from the management of metabolic syndrome, no direct liver therapy has shown clinical efficacy for metabolic liver disease, there is very little for acute alcohol-induced liver disease, and liver transplantation remains the only effective treatment for late-stage liver disease. Traditional pharmacologic interventions have failed to appreciably impact the pathophysiology of alcohol-related liver disease or end-stage liver disease. The difficulties associated with developing liver-specific therapies result from three factors that are common to late-stage liver disease arising from any cause: hepatocyte injury, inflammation, and aberrant tissue healing. Hepatocyte injury results in tissue damage with inflammation, which sensitizes the liver to additional hepatocyte injury and stimulates hepatic stellate cells and aberrant tissue healing responses. In the setting of chronic liver insults, there is progressive scarring, the loss of hepatocyte function, and hemodynamic dysregulation. Regenerative strategies using hepatocyte-like cells that are manufactured from mesenchymal stromal cells may be able to correct this pathophysiology through multiple mechanisms of action. Preclinical studies support their effectiveness and recent clinical studies suggest that cell replacement therapy can be safe and effective in patients with liver disease for whom there is no other option. MDPI 2022-06-22 /pmc/articles/PMC9265349/ /pubmed/35805080 http://dx.doi.org/10.3390/cells11131998 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bogliotti, Yanina
Vander Roest, Mark
Mattis, Aras N.
Gish, Robert G.
Peltz, Gary
Anwyl, Robin
Kivlighn, Salah
Schuur, Eric R.
Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title_full Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title_fullStr Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title_full_unstemmed Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title_short Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review
title_sort clinical application of induced hepatocyte-like cells produced from mesenchymal stromal cells: a literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265349/
https://www.ncbi.nlm.nih.gov/pubmed/35805080
http://dx.doi.org/10.3390/cells11131998
work_keys_str_mv AT bogliottiyanina clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT vanderroestmark clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT mattisarasn clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT gishrobertg clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT peltzgary clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT anwylrobin clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT kivlighnsalah clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview
AT schuurericr clinicalapplicationofinducedhepatocytelikecellsproducedfrommesenchymalstromalcellsaliteraturereview